Detalles de la búsqueda
1.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Haematologica
; 106(10): 2694-2706, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33910333
2.
Experiences of establishing an academic early phase clinical trials unit.
Clin Trials
; 14(4): 349-356, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28532202
3.
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Br J Haematol
; 170(3): 336-48, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25891006
4.
MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia.
BMJ Open
; 11(3): e046225, 2021 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33762245
5.
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial.
Clin Lymphoma Myeloma Leuk
; 21(3): 154-161.e3, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33478922
6.
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
Trials
; 21(1): 826, 2020 Oct 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33008427
7.
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma.
BMC Hematol
; 16: 14, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27190631
Resultados
1 -
7
de 7
1
Próxima >
>>